Clinical Trial Update: Short-course Hypofractionated Radiotherapy in Combination With Raltitrexed and Tislelizumab

View source ↗

Summary

Clinical update for a trial of short-course hypofractionated radiotherapy combined with raltitrexed and tislelizumab in esophageal squamous cell carcinoma; the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Raltitrexed (Raltitrexed)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Anhui Provincial Hospital | Conditions: Esophageal Squamous Cell Carcinoma | Status: RECRUITING